In this video from the Fondazione Internazionale Menarini, Dr. Vittorio Pengo discusses his presentation of the pathophysiology and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). MORE: Find out how doctors diagnosed pulmonary hypertension and CTEPH. Dr. Pengo explains that CTEPH is a treatable disease that occurs in 0.5…

People with chronic thromboembolic pulmonary hypertension (CTEPH) have significantly worse quality of life at their initial assessment, and higher hospitalization rates over time, relative to idiopathic pulmonary arterial hypertension (IPAH) patients, according to a multicenter study in the U.S. Notably, these quality-of-life differences disappeared over time, and CTEPH…

https://www.youtube.com/watch?v=WQnQxSoPkC8 In this video from Experts On CTEPH, Dr. Raymond L. Benza, MD, of Allegheny General Hospital, Pittsburgh, talks about the differential diagnosis of CTEPH. He defines the diseases, explains the symptoms and details how the diagnosis should be made. Learn more about…

Balloon pulmonary angioplasty (BPA) led to significant clinical improvements for people with chronic thromboembolic pulmonary hypertension (CTEPH) when used as an initial therapy or after a pulmonary endarterectomy (PEA) surgery, according to a global observational study. “Our data are in line with previous reports on changes of clinical and…

Pulmonary thromboendarterectomy (PTE) quickly and significantly improved blood flow dynamics and right-sided heart function in people with chronic thromboembolic pulmonary hypertension (CTEPH), with the surgery’s benefits sustained over the long term, a small study shows. Notably, right ventricular (RV) free wall strain, an indirect and non-invasive measure of…

A research journal recently reviewed the use of balloon pulmonary angioplasty (BPA), a new option for people with inoperable chronic thromboembolic pulmonary arterial hypertension. The work, titled “Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension“ appeared in the July 7, 2015 issue of…

Among people with chronic thromboembolic pulmonary hypertension (CTEPH), risk assessments and treatment patterns prior to surgical procedures do not predict outcomes after surgery, a new study from Sweden shows. The results suggest that most CTEPH patients who don’t undergo surgery remain in the same risk category for at least…

Balloon pulmonary angioplasty (BPA) appears to be of multiple benefit to patients with chronic thromboembolic pulmonary hypertension (CTEPH), both in terms of hemodynamics and in other systemic disorders like glycemic control and kidney disease, according to a study published in the journal Circulation, titled “Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients…

Treatment with Uptravi (selexipag) significantly improved blood flow parameters in people with inoperable or persistent chronic thromboembolic pulmonary hypertension (CTEPH) in a Phase 3 clinical trial, although its use did not significantly affect measures of physical abilities. Full trial results are in “Selexipag for the treatment of…

Actelion’s Opsumit (macitentan) made it easier for blood to pass through the lung blood vessels of chronic thromboembolic pulmonary hypertension (CTEPH) patients, a Phase 2 clinical trial suggests. In addition to lowering patients’ lung blood pressure, Opsumit also improved their ability to exercise, and was safe, researchers said. The trail…

Direct oral anticoagulants — a type of blood thinner medication — are a safe and effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), according to a small study. The study, “Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension,” was published in the journal Clinics.

Metabolic differences affecting energy production were observed in endothelial cells — the cells that line blood vessels — from patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). These distinctions could underlie differences in disease mechanisms and necessary treatment approaches, according to a recent study.